GV20 Oncotherapy Closes Series B for Genomics/AI-based mAb Portfolio?
publication date: Oct 15, 2021
GV20 Oncotherapy, a Cambridge, MA-Shanghai biotech, completed a Series B round of undisclosed size to advance its lead immuno-oncology antibody candidate into the clinic. GV20 claims unique expertise in novel target identification and antibody drug discovery in the immuno-oncology field. The company applies its novel genomics platform and AI techniques to speed up antibody drug discovery. The B round was led by Coatue Management, and included existing investors IDG Capital, 3W Investment, Watson Capital, Linear Capital and others. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.